Management of Tachycardia in a Patient on Nystatin for Oral Thrush
Stop the nystatin immediately, as tachycardia is a recognized rare adverse effect of this medication, and switch to an alternative antifungal agent such as clotrimazole troches or oral fluconazole. 1
Immediate Assessment and Management
Confirm the Adverse Reaction
- Tachycardia is a documented rare adverse effect of nystatin according to FDA labeling, along with other cardiovascular manifestations including bronchospasm and facial swelling. 1
- Discontinue nystatin immediately upon recognition of this side effect to prevent potential progression of symptoms. 1
- Assess the severity of tachycardia by measuring heart rate, blood pressure, and evaluating for associated symptoms such as chest discomfort, dyspnea, light-headedness, or syncope. 2
Rule Out Alternative Causes
- Evaluate for other potential causes of tachycardia including:
- Underlying cardiac conditions or supraventricular tachycardia (SVT), which can present with abrupt onset palpitations, chest discomfort, and anxiety. 2
- Concurrent medications or substances that may contribute to tachycardia
- Metabolic derangements (hyperthyroidism, electrolyte abnormalities, dehydration)
- Anxiety or pain related to the oral thrush itself
Alternative Antifungal Treatment Options
For Mild Oral Thrush
- Prescribe clotrimazole troches 10 mg, five times daily for 7–14 days as first-line alternative therapy for mild disease with limited plaques. 3
- This topical approach avoids systemic absorption while maintaining effective antifungal coverage.
For Moderate to Severe Oral Thrush
- Prescribe oral fluconazole 100–200 mg daily for 7–14 days for moderate-to-severe disease characterized by extensive plaques or erythema. 3
- Fluconazole has demonstrated equivalent or superior efficacy compared to nystatin in multiple studies, with better patient convenience and compliance. 4
- The systemic approach with fluconazole serves both therapeutic and diagnostic purposes, confirming the diagnosis while treating the infection. 3
Special Considerations for Denture Wearers
- Mandate concurrent denture disinfection in addition to any antifungal regimen, as inadequate denture hygiene sustains candidal colonization and contributes to treatment failure. 3
- The denture itself serves as a reservoir for Candida species and must be addressed to prevent recurrence. 3
Monitoring and Follow-Up
Cardiovascular Monitoring
- Monitor heart rate and rhythm after discontinuing nystatin to ensure resolution of tachycardia
- If tachycardia persists despite nystatin discontinuation, consider cardiology evaluation to rule out underlying SVT or other cardiac pathology. 2
Antifungal Efficacy Assessment
- Re-examine the oral cavity at 7–14 days to assess for resolution of white plaques, erythema, or angular cheilitis. 3
- If symptoms persist despite appropriate alternative therapy, evaluate for underlying immunosuppressive conditions (HIV with CD4 < 200 cells/µL, uncontrolled diabetes, chronic steroid use, malignancy) that markedly increase risk of recurrent oral candidiasis. 3
Common Pitfalls to Avoid
- Do not continue nystatin once tachycardia is identified, as this is a recognized adverse effect requiring medication discontinuation. 1
- Do not assume all tachycardia is benign—untreated SVT can result in heart failure, pulmonary edema, and myocardial ischemia secondary to increased heart rate. 2
- Do not prescribe empiric long-term antifungal therapy without documented infection, as this promotes antifungal resistance. 3
- Avoid nystatin formulations containing sugar or alcohol in future prescribing, as these additives can be associated with additional side effects, though this is not relevant to the current tachycardia presentation. 5
Reporting Requirements
- Report this suspected adverse reaction to VistaPharm, LLC at 1-888-655-1505 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch, as recommended in the drug labeling. 1